Wed 6/3/2020 19:12 ET
DJIA26269.89538.532.05%TELCO172.262.031.18%GOLD1731.6018.351.06%Shanghai2923.372.050.07%
S&P 5003122.8742.471.36%BANKS363.8119.035.23%OIL35.341.634.61%BITCOIN9627.98103.981.08%
NASDAQ9682.9175.530.78%PHARM614.141.350.22%US/EU1.120.000.00%Futures3057.2519.260.63%
Welcome Stranger!  Please sign up or log in to enable additional features.Sign Up | Mail | Log In
Forum - Wall Street Pit (Keryx Biopharmaceuticals - KERX)    Stock Due Diligence for All

Return Top | Return List | Reply Thread | Search | Add KERX | Ignore KERX
From: SpecGuru (Rep: 63)Date: 2017-01-26 15:55:34
Forum: Wall Street Pit - Thread #673902273 - List KERX msgsMsg #2658091 - Part 1/11 (Rec: 0)
I am a buyer here at $4.75.

*****I am writing drunk*****

Message: Endorse | Reply | Privately | Bookmark | Report Abuse User SpecGuru: Reward | Watch | Ignore

From: SpecGuru (Rep: 63) reply to SpecGuruDate: 2017-01-27 14:48:45
Forum: Wall Street Pit - Thread #673902273 - List KERX msgsMsg #2658286 - Part 2/11 (Rec: 0)
Script numbers came out outstanding. better than it was $7.00. News coming as well.Re: I am a buyer here at $4.75.

*****I am writing drunk*****



Reply to SpecGuru - Msg #2658091 - 01/26/2017 15:55
Message: Endorse | Reply | Privately | Bookmark | Report Abuse User SpecGuru: Reward | Watch | Ignore

From: SpecGuru (Rep: 63) reply to SpecGuruDate: 2017-01-27 15:20:22
Forum: Wall Street Pit - Thread #673902273 - List KERX msgsMsg #2658295 - Part 3/11 (Rec: 0)
Effective from 01/01/2017
Auryxia added to PDL (Preferred Drug List)
Renvela removed from PDL ---- Alternative: Auryxia 210 mg
It is starting...
Re: Script numbers came out outstanding. better than it was $7.00. News coming as...

*****I am writing drunk*****



Reply to SpecGuru - Msg #2658286 - 01/27/2017 14:48
Message: Endorse | Reply | Privately | Bookmark | Report Abuse User SpecGuru: Reward | Watch | Ignore

From: SpecGuru (Rep: 63) reply to SpecGuruDate: 2017-01-27 15:24:52
Forum: Wall Street Pit - Thread #673902273 - List KERX msgsMsg #2658296 - Part 4/11 (Rec: 0)
Here we go: Auryxia. Symphony-based TRx increased 10% while IMS-based TRx increased 7%, respectively wk/wk (502 vs. 458 and 637 vs. 597). No one really knows why KERS dropped from $6.40 to $4.70 in a short time. But I do know I bought back here at $4.75 and that's very important..Re: Script numbers came out outstanding. better than it was $7.00. News coming as...

*****I am writing drunk*****



Reply to SpecGuru - Msg #2658286 - 01/27/2017 14:48
Message: Endorse | Reply | Privately | Bookmark | Report Abuse User SpecGuru: Reward | Watch | Ignore

From: SpecGuru (Rep: 63) reply to SpecGuruDate: 2017-01-28 14:49:41
Forum: Wall Street Pit - Thread #673902273 - List KERX msgsMsg #2658324 - Part 5/11 (Rec: 0)
BIG NEWS!! Harmony, Wellcare, Staywell, they all have put Auryxia on PDL and remove Renvela from PDL
Alternative for Renvela is Auryxia Re:"WellCare provides Medicare and Medicaid managed care health plans for over 4 million members, partners with over 91,000 physicians, and employs over 6,000 associates. Wellcare Health Plans, Inc. is the holding company for several subsidiaries, including WellCare, Staywell, HealthEase, Harmony, and 'Ohana. Regional offices are located in Miami, Florida; Manhattan, New York; New Haven, Connecticut; Baton Rouge, Louisiana; Marietta, Georgia; Houston, Texas; and Chicago, Illinois."
Here we go: Auryxia. Symphony-based TRx increased 10% while IMS-based TRx inc...

*****I am writing drunk*****

Message: Endorse | Reply | Privately | Bookmark | Report Abuse User SpecGuru: Reward | Watch | Ignore

From: SpecGuru (Rep: 63) reply to SpecGuruDate: 2017-02-02 15:04:42
Forum: Wall Street Pit - Thread #673902273 - List KERX msgsMsg #2659137 - Part 6/11 (Rec: 0)
$10.00+ in sight. sNDA filed and it is much bigger market the current infant stage of Auryxia. Really...Re: BIG NEWS!! Harmony, Wellcare, Staywell, they all have put Auryxia on PDL and...

*****I am writing drunk*****

Message: Endorse | Reply | Privately | Bookmark | Report Abuse User SpecGuru: Reward | Watch | Ignore

From: SpecGuru (Rep: 63) reply to SpecGuruDate: 2017-02-02 15:08:08
Forum: Wall Street Pit - Thread #673902273 - List KERX msgsMsg #2659138 - Part 7/11 (Rec: 0)
Drug Approvals Expected to Rise as Trump Pledges to Speed Up Approval Process: Latest Reports on MannKind and Keryx
Accesswire AccesswireFebruary 1, 2017Comment
NEW YORK, NY / ACCESSWIRE / February 1, 2017 / The Biotech Industry has outperformed the broader markets in 2017, despite all the criticism drug makers have been facing. The iShares NASDAQ Biotechnology Index ETF gained 2.84 percent to close at 278.07, up 4.78 percent year-to-date, while the SPDR S&P Biotech ETF spiked 4.14 percent to close at 64.90, up 9.65 percent year-to-date. In comparison, the Dow Jones Industrial Average and the S&P 500 Index have posted gains of 0.51 percent and 1.79 percent, respectively, so far this year. The Biotech Industry received a boost Tuesday after President Trump stated he would loosen drug regulations and push for a faster drug approval process.

Register with us now for your free membership and gain access to our latest research reports at: RDInvesting.com

"We're also gonna be streamlining the process so that, from your standpoint, when you have a drug, you can actually get it approved if it works instead of waiting for many, many years," President Trump said. "The U.S. drug companies have produced extraordinary results for our country, but the pricing has been astronomical for our country."

The U.S. Food and Drug Administration (FDA) approved just 22 new drugs in 2016, less than half of the 45 new drugs approved in 2015, according to Reuters. The number of drugs approved last year was the lowest number of approvals since 2010.

Keryx Biopharmaceuticals (NASDAQ: KERX)

Get Your Up-To-Date Keryx Biopharmaceuticals Research Report Click Here

Keryx Biopharmaceuticals' shares jumped 8.71 percent to close at $4.99 a share Tuesday. The stock traded between $4.47 and $5.05 on volume of 2.27 million shares traded. Keryx is a commercial stage company focused on bringing innovative medicines to people with renal disease. On January 12th, the company announced the publication of results from its pivotal Phase 3 study evaluating ferric citrate for iron deficiency anemia (IDA) in non-dialysis-dependent chronic kidney disease (NDD-CKD) in the online issue of the Journal of the American Society of Nephrology (JASN).

"The results shown in this pivotal study demonstrated that ferric citrate, if approved for this indication, could provide an important new treatment option for people living with chronic kidney disease and iron deficiency anemia who are not on dialysis," said Steven Fishbane, M.D., chief of nephrology for North Shore University Hospital and Long Island Jewish Medical Center.Re: $10.00+ in sight. sNDA filed and it is much bigger market the current infant ...

*****I am writing drunk*****

Message: Endorse | Reply | Privately | Bookmark | Report Abuse User SpecGuru: Reward | Watch | Ignore

From: SpecGuru (Rep: 63) reply to SpecGuruDate: 2017-02-02 15:09:52
Forum: Wall Street Pit - Thread #673902273 - List KERX msgsMsg #2659139 - Part 8/11 (Rec: 0)
Medication/Drug: Auryxia (ferric citrate)
Dosage Form: Tablet
CPT/HCPCS Code(s): J8499
Precertification Routing: N/A
Coverage Criteria/Guidelines: N/A
Benefit Type: Pharmacy
Notes: N/ARe: $10.00+ in sight. sNDA filed and it is much bigger market the current infant ...

*****I am writing drunk*****

Message: Endorse | Reply | Privately | Bookmark | Report Abuse User SpecGuru: Reward | Watch | Ignore

From: SpecGuru (Rep: 63) reply to SpecGuruDate: 2017-02-02 15:32:57
Forum: Wall Street Pit - Thread #673902273 - List KERX msgsMsg #2659147 - Part 9/11 (Rec: 0)
Oxford Health Plans, a UnitedHealthcare company, offers health care benefits to employers and individuals primarily in New York, New Jersey, and Connecticut. Re: Oxford Health Plan Drug Coverage Guideline - Effective Feb. 01, 2017

*****I am writing drunk*****



Reply to SpecGuru - Msg #2659139 - 02/02/2017 15:09
Message: Endorse | Reply | Privately | Bookmark | Report Abuse User SpecGuru: Reward | Watch | Ignore

From: SpecGuru (Rep: 63) reply to SpecGuruDate: 2017-02-03 15:01:03
Forum: Wall Street Pit - Thread #673902273 - List KERX msgsMsg #2659353 - Part 10/11 (Rec: 0)
Setting up. Again, higher script than the best of last week: JAN 27 Auryxia. Symphony-based TRx and IMS-based TRx both increased 2% wk/wk (513 vs. 502 and 650 vs. 637)Re: Oxford Health Plans, a UnitedHealthcare company, offers health care benefits ...

*****I am writing drunk*****

Message: Endorse | Reply | Privately | Bookmark | Report Abuse User SpecGuru: Reward | Watch | Ignore


TheLion.com | About Us | Agreement & Disclaimer | Privacy | Twitter
© 1999- TheLion.com, Inc.